CRISPR Technology Market Expected To Reach $1,715 million by 2023
In the primary research process, various primary sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report.
The primary sources from the supply side include industry experts such as CEOs, vice presidents, marketing directors, technology and innovation directors, and related key executives from various key companies and organizations operating in the market.
The primary sources from the demand side include scientists/researchers from academic & research institutes and government & private laboratories.
Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=134401204
North America is projected to account for the largest share of the CRISPR technology market, by region, during the forecast period.
North America is estimated to account for the largest share of the market in 2018. The large share of CRISPR technology in this region is majorly attributed to the rising government and private funding, presence of major pharma and gene therapy companies, and the adoption of CRISPR in a number of applications. Crops that are treated with CRISPR-based gene editing are not considered as GMOs in the US, which has attracted the attention of agricultural companies to the commercialization of CRISPR-edited crops.
Some of the key players of CRISPR in this region are Cellecta, Inc. (US), Thermo Fisher (US), GeneCopoeia, Inc. (US), Applied StemCell (US), Synthego Corporation (US), OriGene Technologies (US), Horizon Discovery (UK), Merck (Germany), and GenScript (US).
English
Arabic
Français
Español
Português
Türkçe
Dutch
Italiano
Russian
Romaian